The measurement problem in pediatric tooth regeneration trials
The anti-USAG-1 antibody TRG-035 is being developed to induce permanent teeth in children with congenital tooth agenesis. A trial in that population must show that a tooth forms where one was absent, but congenital agenesis in children aged 2 to 5 years is hard to confirm by X-ray alone because the earliest structures, the dental lamina and bud-stage tooth germs, are not yet calcified. Murashima-Suginami and colleagues set out to build imaging biomarkers that could identify those pre-calcified stages and serve as surrogate endpoints in a clinical trial.
What the study did
The paper, published in Journal of Oral Biosciences (volume 68, issue 3, article 100775; DOI 10.1016/j.job.2026.100775), used ferret pups aged 0 to 25 days. The methods section of the peer-reviewed abstract states that the animals were photographed and examined by micro-CT. Ferrets are a standard model for human third-dentition development because their tooth germs develop through comparable bud, cap, and bell stages.
What the abstract reports
The authors report that they developed an imaging biomarker combining MRI and CT/X-rays that could visualize the dental lamina and the pre-calcified tooth germ, structures the abstract describes as previously difficult to identify accurately. The stated goal is to use those landmarks to diagnose congenital tooth agenesis earlier and to supply surrogate endpoints for the clinical development of TRG-035.
Why it matters for the program
For the anti-USAG-1 / TRG-035 program, this is a trial-enabling step rather than a clinical result. The 28 July 2026 field pass noted that the program would be materially changed by “a dated human image showing a tooth in a site that was radiographically empty before treatment.” The present paper addresses the prior question: what imaging readout, in what developmental stage, would make such a claim measurable in a child? The answer proposed here is a multimodal imaging signature of the dental lamina and early tooth germ.
What it does not show
The study is in ferret pups, not children. It reports development and visualization of an imaging biomarker, not induction of a tooth by TRG-035 or any drug. No human safety, pharmacokinetic, or efficacy data are included. The competing-interest statement in the PubMed record notes that the study was funded by Toregem BioPharma Co., Ltd., the developer of TRG-035. The abstract’s methods mention micro-CT, while its results describe a biomarker using both MRI and CT/X-rays; the full paper would be needed to clarify exactly which modalities were acquired and how they were combined.
Where it sits
The paper does not advance TRG-035 from tier 4 to tier 5 on this site’s ladder, because no human efficacy endpoint is reported. It does add a concrete preclinical effort to define how a pediatric efficacy endpoint might be measured, which is a prerequisite for any later claim that the antibody produced a tooth. The current field assessment remains at /field/.
Provenance: the analysis was grounded in the peer-reviewed PubMed/MEDLINE record (PMID 42218011) and the Crossref bibliographic record for the article, per our method at /method/.